Rationale Eslicarbazepine acetate (ESL) is a once-daily oral antiepileptic drug for the
treatment of partial-onset seizures. Adverse events such as dizziness and somnolence …

Objective: To explore the efficacy and safety of eslicarbazepine acetate (BIA 2‐093), a new
antiepileptic drug, as adjunctive therapy in adult patients with partial epilepsy. Methods: A …

Background/Objective: We report on the safety and efficacy of Eslicarbazepine acetate (ESL)
in routine clinical practice. Method: A retrospective multicentre audit of outcomes following …

Objective To examine the influence of titration schedule and maintenance dose on the
incidence and type of treatment-emergent adverse events (TEAEs) associated with …

Eslicarbazepine acetate is an anticonvulsant medication approved in Europe for adjunctive
therapy in adults with partial-onset seizures. FDA approval is expected shortly for use in the …

Eslicarbazepine acetate (ESL) is a voltage‐gated sodium and calcium channel blocker that
was identified as a promising candidate for clinical development in epilepsy through a drug …

For drug development, species differences in drug-metabolism reactions present obstacles
for predicting pharmacokinetics in humans. We characterized the species differences in …

As add-on therapy, phase III clinical trials of eslicarbazepine acetate (ESL) conducted in
patients with refractory partial-onset seizures have shown good efficacy, safety, and …

Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug indicated as
monotherapy for adults with newly diagnosed epilepsy and as adjunctive therapy for the …